Financials · IDXX

IDEXX Laboratories Inc. (IDXX) financials

For the twelve months ended Sep 30, 2026, IDEXX Laboratories Inc. reported $4.66B of revenue and $1.18B of net income.

Revenue, TTM
$4.66B
Revenue growth, YoY
+11.9%
Net income, TTM
$1.18B
Net income growth, YoY
+15.1%
Net margin
25.4%
Free cash flow, TTM
$1.30B
EPS, diluted, TTM
$14.84
EPS growth, YoY
+17.7%
Cash
$197.54M
Total debt
$374.88M
P/E
46.93
P/S
11.90
Market cap
$55.48B
Annual revenue$4.30B
FY2016FY2025
Annual net income$1.06B
FY2016FY2025
Annual free cash flow$1.06B
FY2016FY2025

IDXX revenue and earnings growth

IDXX revenueQ3 2026$1.21B

Quarter YoY
+9.9%
QoQ
-0.2%
FY YoY
+10.4%
5Y CAGR
+9.7%
10Y CAGR
+10.4%

IDXX revenue was $1.21B in fiscal Q3 2026 (ended Sep 30, 2026), up 9.9% from a year earlier and down 0.2% from the prior quarter. For the full fiscal 2025 it was $4.30B, up 10.4% from fiscal 2024. Compound annual growth was +9.7% over 5 years and +10.4% over 10 years. It rose in each of the last 10 fiscal years. Fiscal 2025 is the highest of the 15 fiscal years on file.

IDXX net incomeQ3 2026$317.14M

Quarter YoY
+15.5%
QoQ
-6.3%
FY YoY
+19.3%
5Y CAGR
+12.7%
10Y CAGR
+18.6%

IDXX net income was $317.14M in fiscal Q3 2026 (ended Sep 30, 2026), up 15.5% from a year earlier and down 6.3% from the prior quarter. For the full fiscal 2025 it was $1.06B, up 19.3% from fiscal 2024. Compound annual growth was +12.7% over 5 years and +18.6% over 10 years. It rose in 9 of the last 10 fiscal years. Fiscal 2025 is the highest of the 15 fiscal years on file.

IDXX EPSQ3 2026$4.01

Quarter YoY
+17.9%
QoQ
-6.1%
FY YoY
+22.6%
5Y CAGR
+14.3%
10Y CAGR
+20.4%

IDXX diluted EPS was $4.01 in fiscal Q3 2026 (ended Sep 30, 2026), up 17.9% from a year earlier and down 6.1% from the prior quarter. For the full fiscal 2025 it was $13.08, up 22.6% from fiscal 2024. Compound annual growth was +14.3% over 5 years and +20.4% over 10 years.

IDXX free cash flowQ3 2026$420.79M

Quarter YoY
+13.4%
QoQ
+30.5%
FY YoY
+30.8%
5Y CAGR
+14.3%
10Y CAGR
+22.5%

IDXX free cash flow was $420.79M in fiscal Q3 2026 (ended Sep 30, 2026), up 13.4% from a year earlier and up 30.5% from the prior quarter. For the full fiscal 2025 it was $1.06B, up 30.8% from fiscal 2024. Compound annual growth was +14.3% over 5 years and +22.5% over 10 years. It rose in 8 of the last 10 fiscal years. Fiscal 2025 is the highest of the 15 fiscal years on file.

Export CSV

Income statement

Income statement
Line item
Dec 31, 2025
Dec 31, 2024
Dec 31, 2023
Dec 31, 2022
Dec 31, 2021
Dec 31, 2020
Dec 31, 2019
Dec 31, 2018
Dec 31, 2017
Dec 31, 2016
Revenue$4.30B$3.90B$3.66B$3.37B$3.22B$2.71B$2.41B$2.21B$1.97B$1.78B
Cost of revenue$1.64B$1.52B$1.47B$1.36B$1.33B$1.14B$1.04B$971.70M$871.68M$799.99M
Gross profit$2.66B$2.38B$2.19B$2.00B$1.89B$1.57B$1.37B$1.24B$1.10B$975.44M
Research and development$251.21M$219.79M$190.95M$254.82M$161.01M$141.25M$133.19M$117.86M$109.18M$101.12M
Selling, general and admin$404.79M$442.29M$335.82M$326.25M$309.66M$300.83M$261.32M$244.94M$220.88M$207.02M
Operating income$1.36B$1.13B$1.10B$898.76M$932.03M$694.52M$552.85M$491.33M$413.03M$350.24M
Interest expense$38.85M$31.20M$41.58M$39.86M$29.81M$33.13M$31.05M$34.74M$37.23M$32.05M
Pre-tax income$1.32B$1.11B$1.06B$859.97M$902.65M$661.99M$522.22M$457.74M$381.06M$321.85M
Income tax$264.73M$221.96M$216.13M$180.88M$157.81M$79.85M$94.43M$80.69M$117.79M$99.79M
Net income$1.06B$887.87M$845.04M$679.09M$744.85M$581.78M$427.72M$377.03M$263.14M$222.04M
EPS, basic$13.17$10.77$10.17$8.12$8.74$6.82$4.97$4.34$3.00$2.47
EPS, diluted$13.08$10.67$10.06$8.03$8.60$6.71$4.89$4.26$2.94$2.44
Diluted shares81.0M83.2M84.0M84.6M86.6M86.7M87.5M88.5M89.6M90.9M

Balance sheet

Balance sheet
Line item
Dec 31, 2025
Dec 31, 2024
Dec 31, 2023
Dec 31, 2022
Dec 31, 2021
Dec 31, 2020
Dec 31, 2019
Dec 31, 2018
Dec 31, 2017
Dec 31, 2016
Cash and equivalents$180.07M$288.27M$453.93M$112.55M$144.45M$383.93M$90.33M$123.79M$187.68M$154.90M
Receivables$552.38M$473.57M$457.44M$400.62M$368.35M$331.43M$269.31M$248.85M$234.60M$204.49M
Inventory$377.76M$381.88M$380.28M$367.82M$269.03M$209.87M$195.02M$173.30M$164.32M$158.03M
Current assets$1.41B$1.40B$1.50B$1.10B$955.65M$1.06B$679.64M$654.17M$971.99M$845.58M
Goodwill$414.00M$405.10M$366.00M$361.80M$359.35M$243.35M$239.72M$214.49M$199.87M$178.23M
Total assets$3.35B$3.29B$3.26B$2.75B$2.44B$2.29B$1.83B$1.54B$1.71B$1.53B
Current liabilities$1.15B$1.07B$951.55M$1.24B$763.58M$582.76M$725.34M$770.44M$1.00B$934.57M
Short-term debt$75.00M$167.79M$75.00M$74.98M$75.00M$49.99M$0---
Long-term debt$374.84M$449.79M$622.88M$694.39M$775.21M$858.49M$698.91M---
Total debt$449.84M$617.57M$697.88M$769.37M$850.20M$908.48M$698.91M$601.80M$606.60M$593.70M
Total liabilities$1.75B$1.70B$1.78B$2.14B$1.75B$1.66B$1.65B$1.55B$1.77B$1.64B
Shareholders' equity$1.61B$1.60B$1.48B$608.74M$689.99M$632.79M$177.82M-$9.23M-$53.84M-$108.21M

Cash flow

Cash flow
Line item
Dec 31, 2025
Dec 31, 2024
Dec 31, 2023
Dec 31, 2022
Dec 31, 2021
Dec 31, 2020
Dec 31, 2019
Dec 31, 2018
Dec 31, 2017
Dec 31, 2016
Operating cash flow$1.18B$929.00M$906.51M$542.98M$755.55M$648.06M$459.16M$400.08M$373.28M$338.94M
Capital expenditures$124.68M$120.92M$133.63M$148.84M$119.55M$106.96M$154.97M$115.75M$74.38M$64.79M
Free cash flow$1.06B$808.08M$772.88M$394.15M$636.00M$541.11M$304.19M$284.33M$298.89M$274.16M
Investing cash flow-$136.24M-$207.06M-$125.25M-$195.35M-$292.97M-$109.38M-$205.53M$138.60M-$138.69M-$90.79M
Financing cash flow-$1.16B-$878.07M-$442.00M-$370.94M-$697.41M-$248.42M-$286.41M-$597.80M-$208.02M-$222.20M
Share repurchases$1.22B$837.03M$71.92M$819.71M$746.78M$182.81M$301.66M$369.32M$282.56M$304.09M
Stock-based compensation$60.01M$60.30M$59.74M$49.77M$37.76M$30.95M$39.28M$25.16M$23.52M$19.89M
Depreciation and amortization$145.18M$129.94M$114.91M$111.90M$104.60M$96.00M$88.01M$83.18M$83.14M$78.22M

Key ratios

Key ratios
Line item
Dec 31, 2025
Dec 31, 2024
Dec 31, 2023
Dec 31, 2022
Dec 31, 2021
Dec 31, 2020
Dec 31, 2019
Dec 31, 2018
Dec 31, 2017
Dec 31, 2016
Revenue growth, YoY10.4%6.5%8.7%4.7%18.8%12.5%8.8%12.4%10.9%10.8%
Net income growth, YoY19.3%5.1%24.4%-8.8%28.0%36.0%13.4%43.3%18.5%15.6%
EPS growth, YoY22.6%6.1%25.3%-6.6%28.2%37.2%14.8%44.9%20.5%19.0%
Gross margin61.8%61.0%59.8%59.5%58.8%58.0%56.7%56.1%55.7%54.9%
Operating margin31.6%29.0%30.0%26.7%29.0%25.7%23.0%22.2%21.0%19.7%
Net margin24.6%22.8%23.1%20.2%23.2%21.5%17.8%17.0%13.4%12.5%
Free cash flow margin24.6%20.7%21.1%11.7%19.8%20.0%12.6%12.8%15.2%15.4%
Return on equity66.0%55.7%56.9%111.6%107.9%91.9%240.5%---
Return on assets31.6%27.0%25.9%24.7%30.6%25.4%23.3%24.5%15.4%14.5%
Current ratio1.231.311.570.891.251.820.940.850.970.90
Debt to equity0.280.390.471.261.231.443.93---

Source: XBRL data IDEXX Laboratories Inc. files with the SEC, latest filing dated Nov 2, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures and share counts are restated for stock splits the filings show: 2-for-1, first reported Jul 30, 2015.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

IDXX peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
IDXX$4.66B+11.9%$1.18B25.4%$55.48B
ZTS$9.49B+0.9%$2.51B26.4%$34.06B
NEOG$883.99M-0.3%-$56.10M-6.3%$2.45B
ELAN$5.15B+12.1%-$147.00M-2.9%$13.39B
TMO$47.35B+8.3%$7.07B14.9%$259.44B

IDXX FAQ

9 questions
  • What is IDXX revenue?
    IDEXX Laboratories Inc. (IDXX) reported $4.66B of revenue for the twelve months ended Sep 30, 2026. That is up 11.9% from the year before. Revenue for fiscal 2025 was $4.30B.
  • Is IDXX profitable?
    Yes. IDEXX Laboratories Inc. earned $1.18B in net income for the twelve months ended Sep 30, 2026, a net margin of 25.4%.
  • How much cash and debt does IDXX have?
    IDEXX Laboratories Inc. reported $197.54M in cash and cash equivalents and $374.88M of debt on its most recent balance sheet in SEC filings.
  • How fast is IDXX revenue growing?
    IDEXX Laboratories Inc.'s revenue changed +10.4% in fiscal 2025, to $4.30B. Its compound annual growth rate was +9.7% over 5 years and +10.4% over 10 years.
  • What is IDXX gross margin?
    IDEXX Laboratories Inc.'s gross profit was $2.92B on $4.66B of revenue for the twelve months ended Sep 30, 2026, a gross margin of 62.7%.
  • What is IDXX free cash flow?
    IDEXX Laboratories Inc. generated $1.30B of free cash flow for the twelve months ended Sep 30, 2026, which is operating cash flow of $1.42B less capital expenditures.
  • What is IDXX earnings per share?
    Diluted earnings per share were $14.84 for the twelve months ended Sep 30, 2026, from SEC filings, restated for any stock split those filings show.
  • When did IDXX last report financial results?
    The latest statements here come from IDEXX Laboratories Inc.'s 10-Q filed on Nov 2, 2026, covering the period ended Sep 30, 2026.
  • Where does this IDXX financial data come from?
    Quantisnow builds these statements from the structured XBRL data IDEXX Laboratories Inc. files with the SEC. It is provided for information only and is not investment advice.